Tecovirimat - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic drug sources for tecovirimat and what is the scope of freedom to operate?
Tecovirimat
is the generic ingredient in one branded drug marketed by Siga Technologies and is included in two NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.Tecovirimat has ninety-three patent family members in twenty-two countries.
One supplier is listed for this compound.
Summary for tecovirimat
International Patents: | 93 |
US Patents: | 9 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 24 |
Clinical Trials: | 10 |
Patent Applications: | 127 |
DailyMed Link: | tecovirimat at DailyMed |
Recent Clinical Trials for tecovirimat
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Calmy Alexandra | Phase 3 |
Oswaldo Cruz Foundation | Phase 3 |
ANRS, Emerging Infectious Diseases | Phase 3 |
Pharmacology for tecovirimat
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Siga Technologies | TPOXX | tecovirimat | SOLUTION;INTRAVENOUS | 214518-001 | May 18, 2022 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Siga Technologies | TPOXX | tecovirimat | SOLUTION;INTRAVENOUS | 214518-001 | May 18, 2022 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for tecovirimat
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2866037 | PRODUITS CHIMIQUES, COMPOSITIONS ET PROCEDES DE TRAITEMENT ET DE PREVENTION DES INFECTIONS A ORTHOPOXVIRUS ET DES MALADIES ASSOCIEES (CHEMICALS, COMPOSTIONS, AND METHODS FOR TREATMENT AND PREVENTION OF ORT HOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES) | See Plans and Pricing |
South Korea | 20130135836 | ST-246 LIQUID FORMULATIONS AND METHODS | See Plans and Pricing |
China | 105111131 | Polymorphic forms of ST-246 and methods of preparation | See Plans and Pricing |
Israel | 224430 | Liquid pharmaceutical formulation comprising st-246 and a beta-cyclodextrin, a process of making the liquid formulation, a unit dosage liquid formulation and a process for preparing a water-soluble solid st-246 pharmaceutical formulation | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for tecovirimat
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1638938 | 301177 | Netherlands | See Plans and Pricing | PRODUCT NAME: TECOVIRIMAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1600/001 20220107 |
1638938 | 122022000032 | Germany | See Plans and Pricing | PRODUCT NAME: TECOVIRIMAT ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1600 20220106 |
1638938 | 2290024-5 | Sweden | See Plans and Pricing | PRODUCT NAME: TECOVIRIMAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1600/001 20220107 |
1638938 | 2022C/521 | Belgium | See Plans and Pricing | PRODUCT NAME: TECOVIRIMAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1600 20220107 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.